Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer’s Embeda Joins Abuse-Deterrent Club, But FDA Wants Assurances

This article was originally published in The Pink Sheet Daily

Executive Summary

As with Purdue’s Targiniq, agency requires a post-marketing study to determine whether the new morphine/naltrexone formulation actually deters abuse.

You may also be interested in...



OxyContin’s Abuse-Deterrent Claims Strong, But Stronger Claims Possible

FDA reviewed all the categories of pre-marketing and post-marketing data outlined by guidance for abuse-deterrent opioids, but only in vitro and liking studies made it into the updated label.

OxyContin Revised Labeling Expects Less Abuse Via Injection, Snorting

There will be no generics of original OxyContin; FDA says it can no longer serve as a reference product because it has a greater abuse potential than the reformulation, where Purdue has secured particularly strong language regarding reducing intranasal abuse.

Opioid Abuse-Deterrent Labeling Claim Decision By FDA Could Come Soon

Purdue epidemiological studies indicate reformulation of OxyContin had a positive effect on abuse and misuse of the drug, but the company says continued monitoring is needed to assess whether the positive trend continues.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM011381

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel